Table 6 Predictive factors for DFS by univariate and multivariate analysis

Gender

male vs. female

0.954 (0.594–1.533)

0.847

Year

< 65 vs. ≥65

1.035 (0.740–1.447)

0.842

BMI (kg/m²)

< 24 vs. ≥24

1.026 (0.624–1.699)

0.918

Histology

adenocarcinoma vs. non-adenocarcinoma

0.944 (0.553–1.612)

0.833

Disease Stage

I-II vs. III

1.011 (0.633–1.613)

0.965

Smoking status

smokers vs. non-smokers

1.656 (1.022–2.685)

0.041

1.025 (0.575–1.830)

0.932

Drinking status

non-drinkers vs. drinkers

1.219 (0.705–2.106)

0.478

Surgical type

lobectomy vs. pneumonectomy

2.062 (0.648–6.564)

0.221

T stage

1–2 vs. 3–4

0.567 (0.311–1.035)

0.054

0.719 (0.384–1.345)

0.302

 N stage

0–1 vs. 2

0.329 (0.202–0.534)

< 0.001

0.353 (0.203–0.612)

< 0.001

Radiotherapy

no vs. yes

0.727 (0.348–1.521)

0.398

Baseline cholesterol

low vs. high

1.986 (0.799–4.938)

0.140

1.449 (0.508–4.130)

0.488

Baseline triglyceride

low vs. high

0.620 (0.380–1.011)

0.055

0.652 (0.385–1.103)

0.111

Baseline HDL-C

low vs. high

2.702 (1.291–5.652)

0.008

1.717 (0.735–4.014)

0.021

Baseline LDL-C

low vs. high

1.837 (0.985–3.427)

0.056

0.803 (0.386–1.671)

0.557

Baseline ApoA-I

low vs. high

0.616 (0.266–1.423)

0.256

Baseline ApoB

low vs. high

2.047 (1.073–3.905)

0.030

2.100 (0.999–4.417)

0.050

Cholesterol fluctuation

reduction vs. elevation

1.085 (0.622–1.893)

0.775

Triglyceride fluctuation

reduction vs. elevation

0.984 (0.591–1.638)

0.949

HDL-C fluctuation

reduction vs. elevation

0.475 (0.249–0.904)

0.023

0.609 (0.310–1.200)

0.015

LDL-C fluctuation

reduction vs. elevation

1.027 (0.616–1.711)

0.919

ApoA-I fluctuation

reduction vs. elevation

0.696 (0.356–1.359)

0.289

ApoB fluctuation

reduction vs. elevation

1.037 (0.627–1.717)

0.887